Genmab CEO sees bright future
Genmab is set to make a number of announcements in the coming months, especially relating to the group’s major drug hope daratumumab. The new partnership with Novartis is truly taking off, while a deal with Eli Lilly has run its course.
BY BENJAMIN WERNER CHRISTENSEN
“I’m very satisfied with how things are going. We are very busy, but we keep moving in the right direction,” Genmab CEO Jan van de Winkel tells MedWatch in the wake of the group’s Q1 interim statement, showing a net result of DKK 217 million (USD 32.66 million).
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
This is how Genmab finds M&A targets
For abonnenter
This is Genmab’s main focus for 2015
For abonnenter
Genmab buys clinical assets from French biotech
For abonnenter
